Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors - PubMed
- ️Tue Jan 01 2002
Clinical Trial
. 2002 Aug 15;347(7):472-80.
doi: 10.1056/NEJMoa020461.
Margaret von Mehren, Charles D Blanke, Annick D Van den Abbeele, Burton Eisenberg, Peter J Roberts, Michael C Heinrich, David A Tuveson, Samuel Singer, Milos Janicek, Jonathan A Fletcher, Stuart G Silverman, Sandra L Silberman, Renaud Capdeville, Beate Kiese, Bin Peng, Sasa Dimitrijevic, Brian J Druker, Christopher Corless, Christopher D M Fletcher, Heikki Joensuu
Affiliations
- PMID: 12181401
- DOI: 10.1056/NEJMoa020461
Free article
Clinical Trial
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
George D Demetri et al. N Engl J Med. 2002.
Free article
Abstract
Background: Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors.
Methods: We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor. We assessed antitumor response and the safety and tolerability of the drug. Pharmacokinetics were assessed in a subgroup of patients.
Results: A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily. Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for technical reasons, response could not be evaluated in 7 patients (4.8 percent). No patient had a complete response to the treatment. The median duration of response had not been reached after a median follow-up of 24 weeks after the onset of response. Early resistance to imatinib was noted in 20 patients (13.6 percent). Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common. Gastrointestinal or intraabdominal hemorrhage occurred in approximately 5 percent of patients. There were no significant differences in toxic effects or response between the two doses. Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia.
Conclusions: Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.
Copyright 2002 Massachusetts Medical Society
Comment in
-
A molecular star in the wars against cancer.
Schwartz R. Schwartz R. N Engl J Med. 2002 Aug 15;347(7):462-3. doi: 10.1056/NEJMp020079. N Engl J Med. 2002. PMID: 12181399 No abstract available.
-
Effective therapy for advanced gastrointestinal stromal tumors.
Collins CG, O'Sullivan GC, Shanahan F. Collins CG, et al. Gastroenterology. 2003 Apr;124(4):1151-3. doi: 10.1016/s0016-5085(03)70070-5. Gastroenterology. 2003. PMID: 15534977 No abstract available.
Similar articles
-
Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD. Demetri GD. Semin Oncol. 2001 Oct;28(5 Suppl 17):19-26. Semin Oncol. 2001. PMID: 11740803 Review.
-
[Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
Wan DS, Wu XJ, Pan ZZ, Zhou ZW, Chen G, Li LR, Lu ZH, Ding PR. Wan DS, et al. Zhonghua Yi Xue Za Zhi. 2006 Nov 21;86(43):3064-7. Zhonghua Yi Xue Za Zhi. 2006. PMID: 17288838 Chinese.
-
Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK. Ryu MH, et al. Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23. Oncology. 2009. PMID: 19307738 Clinical Trial.
-
[Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
Shen L, Jin ML. Shen L, et al. Zhonghua Zhong Liu Za Zhi. 2004 Nov;26(11):697-9. Zhonghua Zhong Liu Za Zhi. 2004. PMID: 15777512 Chinese.
-
Sawaki A, Yamao K. Sawaki A, et al. Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S44-9. doi: 10.1007/s00280-004-0886-y. Cancer Chemother Pharmacol. 2004. PMID: 15309514 Review.
Cited by
-
Kanda T, Nishida T, Wada N, Kobayashi O, Yamamoto M, Sawaki A, Boku N, Koseki M, Doi T, Toh Y, Kakeji Y, Sugiyama T, Komatsu Y, Kikuchi S, Ogoshi K, Katai H, Miyachi K, Hirota S, Ohtsu A. Kanda T, et al. Int J Clin Oncol. 2013 Feb;18(1):38-45. doi: 10.1007/s10147-011-0339-7. Epub 2011 Nov 23. Int J Clin Oncol. 2013. PMID: 22105894 Clinical Trial.
-
An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.
Patel SR, Reichardt P. Patel SR, et al. Cancer. 2021 Jul 1;127(13):2187-2195. doi: 10.1002/cncr.33630. Epub 2021 May 11. Cancer. 2021. PMID: 33974733 Free PMC article. Review.
-
Candidate cancer-targeting agents identified by expression-profiling arrays.
Termglinchan V, Wanichnopparat W, Suwanwongse K, Teeyapant C, Chatpermporn K, Leerunyakul K, Chuadpia K, Sirimaneethum O, Wijitworawong P, Mutirangura W, Aporntewan C, Vinayanuwattikun C, Mutirangura A. Termglinchan V, et al. Onco Targets Ther. 2013 Apr 23;6:447-58. doi: 10.2147/OTT.S42858. Print 2013. Onco Targets Ther. 2013. PMID: 23637543 Free PMC article.
-
Targeted therapy in rare cancers--adopting the orphans.
Munoz J, Kurzrock R. Munoz J, et al. Nat Rev Clin Oncol. 2012 Nov;9(11):631-42. doi: 10.1038/nrclinonc.2012.160. Epub 2012 Sep 11. Nat Rev Clin Oncol. 2012. PMID: 22965154 Review.
-
Fukuda M, Mukohara T, Kuwata T, Sunami K, Naito Y. Fukuda M, et al. JCO Precis Oncol. 2024 Aug;8:e2300649. doi: 10.1200/PO.23.00649. JCO Precis Oncol. 2024. PMID: 39116355 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources